AWAnnemarie Woolston

Annemarie Woolston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annemarie Woolston has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Benny Chain

    Division of Infection and Immunity, University College London

    4 shared publications
  • Allan Hackshaw

    Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK

    3 shared publications
  • Andrew Georgiou

    Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK

    3 shared publications
  • Andrew J. S. Furness

    Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK

    3 shared publications
  • Assma Ben Aissa

    Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK

    3 shared publications
  • Charles Swanton

    Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

    3 shared publications

Latest Publications

  • Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

    by Kroopa Joshi, Marc Robert de Massy, Mazlina Ismail, James L. Reading, Imran Uddin, Annemarie Woolston, Emine Hatipoglu, Theres Oakes, Rachel Rosenthal, Thomas Peacock, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • The T cell differentiation landscape is shaped by tumour mutations in lung cancer

    by Ehsan Ghorani, James L. Reading, Jake Y. Henry, Marc Robert de Massy, Rachel Rosenthal, Virginia Turati, Kroopa Joshi, Andrew J. S. Furness, Assma Ben Aissa, Sunil Kumar Saini, et al.

    Tumour mutational burden (TMB) predicts immunotherapy outcome in non-small cell lung cancer (NSCLC), consistent with immune recognition of tumour neoantigens. However, persistent antigen exposure is detrimental for T cell function. How TMB affects CD4 and CD8 T cell differentiation in untreated tumours and whether this affects patient outcomes is unknown. Here, we paired high-dimensional flow cytometry, exome, single-cell and bulk RNA sequencing from patients with resected, untreated NSCLC to examine these relationships. TMB was associated with compartment-wide T cell differentiation skewing, characterized by loss of TCF7-expressing progenitor-like CD4 T cells, and an increased abundance of dysfunctional CD8 and CD4 T cell subsets with strong phenotypic and transcriptional similarity to neoantigen-reactive CD8 T cells. A gene signature of redistribution from progenitor-like to dysfunctional states was associated with poor survival in lung and other cancer cohorts. Single-cell characterization of these populations informs potential strategies for therapeutic manipulation in NSCLC.


  • Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

    by TRACERx consortium, Kroopa Joshi, Marc Robert de Massy, Mazlina Ismail, James L. Reading, Imran Uddin, Annemarie Woolston, Emine Hatipoglu, Theres Oakes, Rachel Rosenthal, et al.

    Somatic mutations together with immunoediting drive extensive heterogeneity within non-small-cell lung cancer (NSCLC). Herein we examine heterogeneity of the T cell antigen receptor (TCR) repertoire. The number of TCR sequences selectively expanded in tumors varies within and between tumors and correlates with the number of nonsynonymous mutations. Expanded TCRs can be subdivided into TCRs found in all tumor regions (ubiquitous) and those present in a subset of regions (regional). The number of ubiquitous and regional TCRs correlates with the number of ubiquitous and regional nonsynonymous mutations, respectively. Expanded TCRs form part of clusters of TCRs of similar sequence, suggestive of a spatially constrained antigen-driven process. CD8+ tumor-infiltrating lymphocytes harboring ubiquitous TCRs display a dysfunctional tissue-resident phenotype. Ubiquitous TCRs are preferentially detected in the blood at the time of tumor resection as compared to routine follow-up. These findings highlight a noninvasive method to identify and track relevant tumor-reactive TCRs for use in adoptive T cell immunotherapy.


  • Open Access

    Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function

    by Sharyn Thomas, Fiyaz Mohammed, Rogier M. Reijmers, Annemarie Woolston, Theresa Stauss, Alan Kennedy, David Stirling, Angelika Holler, Louisa Green, David Jones, et al.

    TCR-gene-transfer is an efficient strategy to produce therapeutic T cells of defined antigen specificity. However, there are substantial variations in the cell surface expression levels of human TCRs, which can impair the function of engineered T cells. Here we demonstrate that substitutions of 3 amino acid residues in the framework of the TCR variable domains consistently increase the expression of human TCRs on the surface of engineered T cells.The modified TCRs mediate enhanced T cell proliferation, cytokine production and cytotoxicity, while reducing the peptide concentration required for triggering effector function up to 3000-fold. Adoptive transfer experiments in mice show that modified TCRs control tumor growth more efficiently than wild-type TCRs. Our data indicate that simple variable domain modifications at a distance from the antigen-binding loops lead to increased TCR expression and improved effector function. This finding provides a generic platform to optimize the efficacy of TCR gene therapy in humans.


  • Open Access

    Genetic loci associated with an earlier age at onset in multiplex schizophrenia

    by Annemarie L. Woolston, Po-Chang Hsiao, Po-Hsiu Kuo, Shi-Heng Wang, Yin-Ju Lien, Chih-Min Liu, Hai-Gwo Hwu, Tzu-Pin Lu, Eric Y. Chuang, Li-Ching Chang, et al.

    An earlier age at onset (AAO) has been associated with greater genetic loadings in schizophrenia. This study aimed to identify modifier loci associated with an earlier AAO of schizophrenia. A genome-wide association analysis (GWAS) was conducted in 94 schizophrenia probands with the earliest AAO and 91 with the latest AAO. Candidate single nucleotide polymorphisms (SNPs) were then genotyped in the co-affected siblings and unrelated probands. Multi-SNP genetic risk scores (GRS) composed of the candidate loci were used to distinguish patients with an early or late AAO. The 14-SNP GRS could distinguish the co-affected siblings (n = 90) of the earliest probands from those (n = 91) of the latest probands. When 132 patients with an earlier AAO and 158 patients with a later AAO were included, a significant trend in the 14-SNP GRS was detected among those unrelated probands from 4 family groups with the earliest, earlier, later, and latest AAO. The overall effect of the 14 SNPs on an AAO in schizophrenia was verified using co-affected siblings of the GWAS probands and trend effect across unrelated patients. Preliminary network analysis of these loci revealed the involvement of PARK2, a gene intensively reported in Parkinson’s disease and schizophrenia research.